Using AI to evaluate the severity of gastric intestinal metaplasia
Automatic Evaluation of the Severity of Gastric Intestinal Metaplasia With Pathology Artificial Intelligence Diagnosis System: a Diagnostic Test
Shandong University · NCT05447221
This study is testing a new AI system that helps doctors quickly identify and measure the severity of a condition related to stomach cancer using fewer biopsies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 40 Years to 75 Years |
| Sex | All |
| Sponsor | Shandong University (other) |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT05447221 on ClinicalTrials.gov |
What this trial studies
This study aims to develop a Digital Pathology Artificial Intelligence Diagnosis System (DPAIDS) to automatically identify tumor areas in whole slide images and quantify the severity of intestinal metaplasia. The OLGIM staging system, which assesses gastric cancer risk, typically requires multiple biopsies, but this approach seeks to streamline the process due to a shortage of pathologists. By leveraging advancements in digital pathology and deep learning, the study will prospectively collect biopsies for model validation, potentially improving diagnostic efficiency and accuracy.
Who should consider this trial
Good fit: Ideal candidates are patients aged 40-75 who are undergoing gastroscopy examinations and biopsies.
Not a fit: Patients with severe comorbidities or those who have had previous stomach surgeries may not benefit from this study.
Why it matters
Potential benefit: If successful, this system could significantly enhance the early detection and assessment of gastric cancer risk in patients.
How similar studies have performed: Other studies utilizing AI in pathology have shown promise, indicating that this approach could be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients aged 40-75 years who undergo the gastroscopy examination and biopsy Exclusion Criteria: * patients with severe cardiac, cerebral, pulmonary or renal dysfunction or psychiatric disorders who cannot participate in gastroscopy * patients with previous surgical procedures on the stomach * patients with contraindications to biopsy * patients who refuse to sign the informed consent form
Where this trial is running
Jinan, Shandong
- Department of Gastroenterology, Qilu Hospital, Shandong University — Jinan, Shandong, China (RECRUITING)
Study contacts
- Study coordinator: Yanqing Li, MD, PhD
- Email: liyanqing@sdu.edu.cn
- Phone: 0531182169385
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Gastric Intestinal Metaplasia, Artificial Intelligence, Pathology, Gastric Cancer, gastric cancer, Digital Pathology, Whole Slide Image